Gene: FLT3 ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs759272576
rs759272576
FLT3
0.010 GeneticVariation BEFREE Targeted next-generation sequencing at the time of AML progression on gilteritinib identified treatment-emergent mutations that activate RAS/MAPK pathway signaling, most commonly in <i>NRAS</i> or <i>KRAS.</i> Less frequently, secondary <i>FLT3</i>-F691L gatekeeper mutations or <i>BCR-ABL1</i> fusions were identified at progression. 31088841

2019
dbSNP: rs1244282842
rs1244282842
FLT3
0.010 GeneticVariation BEFREE From Six Gene Polymorphisms of the Antioxidant System, Only GPX Pro198Leu and GSTP1 Ile105Val Modulate the Risk of Acute Myeloid Leukemia. 26823947

2016
dbSNP: rs374234147
rs374234147
FLT3
0.010 GeneticVariation BEFREE We identified five IDH1 mutations that were novel to AML: (1) c.299 G>A, p.R100Q; (2) c.311G>T, p.G104V; (3) c.322T>C, p.F108L; (4) c.356G>A, p.R119Q; and (5) c.388A>G, p.I130V. 24376688

2013
dbSNP: rs35602083
rs35602083
FLT3
0.010 GeneticVariation BEFREE The FLT3 D324N variant was present in 42 cases (6.4%), but it was not associated with a specific AML subtype and did not show an elevated leukocyte count, as do other FLT3 mutations. 16320249

2006
dbSNP: rs1057519762
rs1057519762
FLT3
G 0.700 GeneticVariation CLINVAR Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. 24619500

2014
dbSNP: rs1057519765
rs1057519765
FLT3
A 0.700 GeneticVariation CLINVAR Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. 24619500

2014
dbSNP: rs1057519767
rs1057519767
FLT3
C 0.700 GeneticVariation CLINVAR Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. 24619500

2014
dbSNP: rs1057519768
rs1057519768
FLT3
C 0.700 GeneticVariation CLINVAR Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. 24619500

2014
dbSNP: rs1057519769
rs1057519769
FLT3
A 0.700 GeneticVariation CLINVAR Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. 24619500

2014
dbSNP: rs121909646
rs121909646
FLT3
A 0.700 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs121913486
rs121913486
FLT3
T 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs121913490
rs121913490
FLT3
C 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs121913491
rs121913491
FLT3
C 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs1057519726
rs1057519726
FLT3
G 0.700 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013
dbSNP: rs1057519726
rs1057519726
FLT3
G 0.700 CausalMutation CLINVAR The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. 23783394

2013
dbSNP: rs1057519726
rs1057519726
FLT3
G 0.700 CausalMutation CLINVAR Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. 23321257

2013
dbSNP: rs1057519726
rs1057519726
FLT3
G 0.700 CausalMutation CLINVAR The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. 23714533

2013
dbSNP: rs1057519762
rs1057519762
FLT3
G 0.700 GeneticVariation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs1057519765
rs1057519765
FLT3
A 0.700 GeneticVariation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs1057519767
rs1057519767
FLT3
C 0.700 GeneticVariation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs1057519768
rs1057519768
FLT3
C 0.700 GeneticVariation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs1057519769
rs1057519769
FLT3
A 0.700 GeneticVariation CLINVAR Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. 23430109

2013
dbSNP: rs121909646
rs121909646
FLT3
A 0.700 CausalMutation CLINVAR Mutational landscape of AML with normal cytogenetics: biological and clinical implications. 23261068

2013
dbSNP: rs121909646
rs121909646
FLT3
A 0.700 CausalMutation CLINVAR Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. 24046014

2013
dbSNP: rs121909646
rs121909646
FLT3
G 0.700 CausalMutation CLINVAR The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. 23714533

2013